RCUS Stock — Arcus Biosciences, Inc.

Arcus Biosciences, Inc. (RCUS)

Updated October 16, 2026.

RCUS is a Stock. Total return is 30.1% over the past 8.6 years, 186.8 points behind SPY at 216.9%.

Arcus Biosciences is a clinical-stage biopharmaceutical company developing cancer immunotherapy and oncology treatments, including programs targeting kidney cancer, lung cancer, gastrointestinal cancers, and pancreatic cancer through various mechanisms such as HIF-2a inhibition, checkpoint blockade, and enzyme inhibition. The company does not currently distribute to shareholders. Arcus appeals to investors seeking exposure to early-stage biotech development with potential for significant upside if its clinical programs succeed, though investors should understand the substantial risks inherent in clinical-stage drug development.

RCUS performance versus SPY

Price and return data through 2026-10-16.

Total return is 30.1% over the past 8.6 years, 186.8 points behind SPY at 216.9%. Over the past year its total return — price change plus distributions reinvested — is 33.3%. Its deepest 1-year drawdown was 29.9%.

RCUS key facts

Asset type

Stock

Asset class

Equity

Inception date

03/15/2018

Distribution frequency

None

Last close

$22.12 (as of 2026-10-16)

Market cap

$2,782,102,343

Average volume

1425531.0

Beta

0.938

Payout ratio

0.0%

EPS

$-3.91

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RCUS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 29.9%.

Who may consider RCUS — and who may not

It is a weaker fit for investors who need monthly cash flow (RCUS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on RCUS

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions